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1. 
METHOD AND APPARATUS FOR CANCER 
SCREENING 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority from U.S. Provisional 
Application Ser. No. 61/284.336, which has a filing date of 
Dec. 17, 2009. 
FIELD OF THE INVENTION 
The present invention generally relates to an apparatus and 
method for Screening for cancer. In particular, the apparatus 
and method for screening for cancer is based on the detection 
of pteridine molecules in biological samples, for example, 
urine samples. 
BACKGROUND OF THE INVENTION 
Cancer is the second leading cause of death in the United 
States. To date, approximately 50% of all neoplasms are 
treated with multi-disciplinary cancer treatment. Neoplastic 
disorders differ widely in etiology, pathology, and natural 
disease history. The principle behind detection at earlier 
stages of disease progression yielding higher cure rates 
applies to virtually all Solid tumors. As a result, cancer Screen 
ing has been an area of elevated research and clinical interest 
and has greatly impacted cancer diagnoses and treatments. 
Biomarkers are compounds in the body that may be indica 
tive of medical conditions or biological states. Hayes et al. 
defined a cancer biomarker as "a molecular, cellular, tissue, or 
process-based alteration that provides indication of current, 
or more importantly, future behavior of cancer.’ See Hayes D 
F. Bast RC, Desch CE, et al. Tumor marker utility grading 
system: a framework to evaluate clinical utility of tumor 
markers. J. Natl. Cancer Inst. 1996, 88, pp. 1456-66. These 
biological and physiological indicators could include a broad 
range of biochemical entities, such as nucleic acids, proteins, 
Sugars, lipids, and Small metabolites, as well as whole cells, in 
either specific tissues or in circulation. Today, circulating 
cancer cells are becoming a powerful tool in “microscopic' 
cancer Screening. Detection of biomarkers, either individu 
ally or as larger sets or patterns, can be accomplished by a 
wide variety of methods, ranging from biochemical analysis 
of blood or tissue samples to biomedical imaging. 
Normally, patients are hesitant to damage their organs and 
tissues to give samples during the disease diagnosis process. 
They may also be reluctant to give blood for diagnostic tests. 
Therefore, development of a noninvasive diagnostic tech 
nique for early cancer screening is very crucial for all popu 
lations. Noninvasive diagnosis involves procedures that do 
not penetrate the body mechanically, nor break the skin or 
involve penetration through a body cavity. It does not require 
an incision into the body or the removal of biological tissue. 
Currently, many researchers are focusing on noninvasive 
means to diagnose cancer by analyzing cancer biomarkers in 
urine, which is more easily collected than tissue or blood 
samples. 
Recently, pteridine molecules have become a focal point of 
cancer screening research. See Rokos K. Rokos H., Frisius 
H., Huefner M., Pteridines in Cancer and Other Diseases, 
1983, pp. 153-7: Noronha J. M., Trehan S., Urinary Excretion 
of Total Pteridines in Cancer, 1990, pp. 515-8; Murr C. 
Widner B. Wirleitner B., Fuchs D., Neopterinas a Marker for 
Immune System Activation, Curr. Drug. Metab. 2002, 3, pp. 













Analysis in Urine by Capillary Electrophoresis Using Laser 
Induced Fluorescence Detection, Anal. Chem., 1999, 71, pp. 
1265-9; Gibbons S. E., Stayton I., Ma Y. Optimization of 
Urinary Pteridine Analysis Conditions by CE-LIF for Clini 
cal Use in Early Cancer Detection, Electrophoresis, 2009, 30. 
pp. 3591-7: Fuchs D. Kramer A., Reibnegger G. et al., Neop 
terin and Beta 2-Microglobulin as Prognostic Indices in 
Human Immunodeficiency Virus Type 1 Infection, Infection, 
1991, 19 (Suppl. 2), pp. S98-S102. Pteridines are a group of 
heterocyclic compounds contained in the body and excreted 
in the urine. Research into the use of pteridines as cancer 
biomarkers investigated the urinary pteridine levels as poten 
tial biomarkers for noninvasive diagnosis of cancer. Pte 
ridines are naturally occurring heterocyclic compounds 
involved in the biosynthetic pathways of cofactors and vita 
mins. Research suggests that concentrations of pteridines 
found in urine differ between cancer patients and non-cancer 
patients. For example, it has been reported that the neopterin/ 
biopterin ratio differs among cancer patients and non-cancer 
patients. See Stea, B. et al., Clin. Chim. Acta, 1981, 113, pp. 
231-242, which reported that the neopterin/biopterin level for 
cancer patients was 1.6 times that of normal Subjects. Addi 
tionally, the amount of pteridine and pattern of expression in 
the urine may vary with specific neoplasms and clinical stage. 
Thus, urinary pteridine assays have been studied as a potential 
cancer Screening method 
Analysis of pteridines has been performed with several 
techniques, such as thin layer chromatography (TLC), high 
performance liquid chromatography (HPLC) combined with 
UV or fluorescence detection, and conventional capillary 
electrophoresis with laser induced fluorescence detection 
(CE-LIF). For example, a method has been reported describ 
ing the determination of total oncopterin, neopterin, and biop 
terin in human urine using solid phase extraction with 6.7- 
dimethylpterin as internal standard and gradient HPLC with 
fluorescence detection. See Tomandlet al., Journal of Sepa 
ration Science, Vol. 26, 8, pp. 674-678, June 2003. However, 
the detection limit for oncopterin reported in the study is 
relatively high at about 1.43 mol/L. Moreover, the reported 
urine preparation time is still long (about 2 hr), since the study 
utilized full hydrolysis vs. oxidation of the pteridines. 
In U.S. Pat. No. 6,576,105 B1 by Yinfa Ma, the inventor 
also described a detection method for pteridines in urine 
using the conventional CE-LIF technology. Even though the 
patented CE-LIF technology has shown promising improve 
ments in feasibility for clinical laboratories, the patented CE 
LIF technology has limitation on the accuracy and reproduc 
ibility because of the complexity of urine samples. 
Therefore, there is a need to provide a new and improved 
cancer Screening method by pteridine urine detection using 
CE-LIF. There is also a need to provide an improved CE-LIF 
apparatus for the pteridine urine detection to achieve a non 
invasive, sensitive, fast, simple, and cost effective cancer 
screening tool. 
SUMMARY OF THE INVENTION 
The present invention is directed to a cancer Screening 
method. The cancer screening method of the present inven 
tion detects pteridine concentration levels in a subject’s bio 
logical sample Such as urine. The concentration of the pteri 
dine compound in the patient’s biological sample is 
compared to an expected concentration of the pteridine com 
pound in either a healthy mammal of the same species or in a 
cancer-bearing mammal of the same species. 
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According to some embodiments of the invention, the 
inventive cancer Screening method comprises the step of 
detecting oncopterin level in a Subject's urine sample. 
The inventive method may further comprise the step of 
detecting concentration levels of other pteridine to determine 
what type(s) of cancer that a subject may develop. 
According to some embodiments of the method of the 
present invention, a biological sample, e.g., a Subject's urine 
sample, is collected and pretreated prior to analysis. Pretreat 
ment involves a first step of oxidizing the pteridines in the 
sample by exposure to a composition containing an oxidizing 
agent. Pteridines are oxidized to their fully oxidized state. In 
Some preferred embodiments, the oxidizing agent is iodine. 
Pretreatment may involve alkalinization of the pteridine con 
taining sample by exposure to an alkaline Solution, which 
assists in the extraction of the pteridines from the urine 
sample as pteridines have a higher solubility factor in alkaline 
Solutions. 
According to the method of the present invention, the 
sample may be centrifuged and the Supernatant diluted with a 
buffer solution in order to prepare the sample for separation 
via capillary electrophoresis. The treated Sample is then intro 
duced subjected to capillary electrophoresis by using either a 
gravimetric, electrokinetic, or pressure injection technique. 
The separated sample is then irradiated by a non-polarizing 
light Source, and the fluorescence emission is detected by a 
fluorescence detection means, such as a photomultiplier tube, 
to collect the fluorescence. 
The present invention is further directed to a capillary 
electrophoresis lased induced fluorescence (CE-LIF) appara 
tus. The CE-LIF employs a combination of lenses, filters, and 
irises to enhance stability and reproducibility of the urine 
pteridine detection. The lenses, filters, and irises enhance 
detection by substantially reducing laser scatter from the 
excitation source and from the capillary, thereby producing a 
stable, low noise baseline that enables low limits of detection. 
The CE-LIF apparatus employs a combination of a confocal 
lens having greater than 10x magnification placed in the 
range of 45 to 90 degrees from the laser path to collect and 
focus fluorescence emission from the sample. The CE-LIF 
apparatus employs at least one physical iris for removing 
scattered light either from the filtered non-polarized laser or 
from any fluorescence generated by the device. A device 
structured with the high magnification confocal lens and iris 
yields a very low noise baseline, enabling low limits of detec 
tion of pteridines in urine and other samples. 
In some embodiments, the inventive apparatus includes 1) 
a non-polarized excitation source emitting non-polarized 
laser at a non-traditional Solid state laser wavelength. In some 
embodiments, the inventive apparatus includes 2) a first fil 
tration means for filtering the non-polarized laser. In some 
embodiments, the inventive apparatus includes 3) a focal lens 
that focuses the filtered, non-polarized laser onto a capillary, 
the pathway by which the intended sample is separated and 
exposed to the filtered, non-polarized laser via a detection 
window on the capillary. In some embodiments, the inventive 
apparatus includes 4) a sample holder with a detection win 
dow that facilitates the mounting of an electrophoresis capil 
lary. In some embodiments, the inventive apparatus includes 
5) a capillary electrophoresis device that is capable of sepa 
rating the specific compounds of interest (pteridines) within 
the samples and delivering the sample to the detection win 
dow of the capillary mounted within the sample holder. 
In some embodiments, the inventive apparatus includes 6) 
a confocal lens greater than 10x magnification placed in the 
range of 45 to 90 degrees from the laser path to collect and 














embodiments, the inventive apparatus includes 7) a second 
filtration means for filtering non-pteridine fluorescence gen 
erated by any compound other than those in the pteridine 
family or for filtering background scattering light from the 
laser. In some embodiments, the inventive apparatus includes 
8) a physical iris for removing any scattering either from the 
filtered non-polarized laser or from any fluorescence gener 
ated by the device. The physical iris controls the light beam 
size and minimizes the scattered light. In some embodiments, 
the inventive apparatus includes 9) a detection means for 
detecting the filtered fluorescence emission generated by the 
pteridines in the samples. In some embodiments, the inven 
tive apparatus includes 10) a current to Voltage (I to V) con 
verter to communicate the raw output from the electrons from 
the compounds of interest undergoing fluorescent decay to 
the digital input of the device collecting the output. In some 
embodiments, the inventive apparatus includes 11) a control 
means for independently controlling the stations of the laser 
focal lens, capillary mount, collection lens and detector to 
prevent any mechanical cross-talk from one stage to the oth 
ers that may adversely affect the resulting data. 
Briefly, therefore, the invention is directed to a method of 
detecting a pteridine compound concentration in a biological 
sample obtained from a mammal, the method comprising 
treating the biological sample with an oxidizing agent in a 
concentration sufficient such that at least about 90 wt % of 
said concentration of pteridine compound in the biological 
sample is in its fully oxidized State; Subjecting the sample to 
capillary electrophoresis using laser-induced fluorescence 
(CE-LIF) to cause the oxidized portion of said concentration 
of said pteridine compound to emit fluorescent light; detect 
ing the emitted fluorescence light; and analyzing the emitted 
fluorescence light to determine the concentration of the pte 
ridine compound in the biological sample. 
The invention is also directed to a method for screening for 
cancer in a mammal, the method comprising quantitatively 
measuring a concentration of oncopterin (N2-(3-aminopro 
pyl) biopterin) in a biological sample from the mammal by 
capillary electrophoresis-lased induced fluorescence; and 
comparing the concentration of oncopterin (N2-(3-amino 
propyl) biopterin) in the sample with the concentration of 
oncopterin (N2-(3-aminopropyl) biopterin) in a biological 
sample from a healthy mammal of the same species to deter 
mine whether the concentrations of oncopterin (N2-(3-ami 
nopropyl) biopterin) is significantly elevated or decreased. 
In a further aspect, the invention is directed to an apparatus 
for determining a concentration of pteridine in a biological 
sample, the apparatus comprising an excitation source emit 
ting non-polarized laser light capable of inducing the pteri 
dine to emit fluorescent light and having a power output of at 
least about 1 mW; an electrophoresis capillary having a detec 
tion window and being capable of separating the pteridine 
from other components of the biological sample; a first opti 
cal system for focusing the non-polarized laser light onto the 
detection window of the capillary, wherein the first optical 
system comprises a focal lens; a light collection device for 
collecting fluorescent light emitted from the pteridine in the 
biological sample; and a second optical system for magnify 
ing fluorescent light emitted from the pteridine and for focus 
ing the magnified fluorescent light onto the light collection 
device, wherein the second optical system comprises a con 
focal lens having a magnification greater than 10x and a 
physical iris diaphragm. 
Other objects and features of the invention will be in part 
apparent and in part pointed out hereinafter. 
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BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic design of the capillary electrophore 
sis with laser induced fluorescence detection (CE-LIF) appa 
ratus of the present invention. 
FIG. 2 is an electropherogram of the eight pteridine stan 
dards. The experimental conditions are described in the 
Example. 
FIG. 3 is a box plot of 6,7-dimethylpterin levels in cancer 
urine samples (n=38) and normal urine samples (n=17). 
FIG. 4 is a box plot of 6-biopterin levels in cancer urine 
samples (n=38) and normal urine samples (n=17). 
FIG. 5 is a box plot of 6-hydroxymethylpterin levels in 
cancer urine samples (n=38) and normal urine samples 
(n=17). 
FIG. 6 is a box plot of D-(+)-neopterin levels in cancer 
urine samples (n=38) and normal urine samples (n=17). 
FIG. 7 is a box plot of pterin levels in cancer urine samples 
(n=38) and normal urine samples (n=17). 
FIG. 8 is a box plot of isoxanthopterin levels in cancer urine 
samples (n=38) and normal urine samples (n=17). 
FIG. 9 is a box plot of xanthopterin levels in cancer urine 
samples (n=38) and normal urine samples (n=17). 
FIG. 10 is a box plot of xanthopterin levels in cancer urine 
samples (n=38) and normal urine samples (n=17). 
FIG. 11 is a box plot of isoxanthopterin levels in breast 
cancer urine samples (n=12), lung cancer urine samples 
(n=9), and normal urine samples (n=17). 
FIG. 12 is a box plot of xanthopterin levels in breast cancer 
urine samples (n=12), lung cancer urine samples (n=9), and 
normal urine samples (n=17). 
FIG. 13 is a scatter plot of creatinine levels in cancer urine 
samples (n=38) and normal urine samples (n=17). 
FIG. 14 is an electrophergram generated according to 
Example 2. 
Corresponding reference characters indicate correspond 
ing parts throughout the drawings. 
DESCRIPTION OF THE EMBODIMENT(S) OF 
THE INVENTION 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
belongs. All publications, patent applications, patents, and 
other references mentioned herein are incorporated by refer 
ence in their entirety. 
The present invention provides a cancer Screening method 
for detecting pteridine levels in a biological sample, e.g., a 
urine sample, using capillary electrophoresis-laser induced 
fluorescence (CE-LIF) technology. 
The major pteridines molecules that are detected in accor 
dance with this invention are one or more from among 6.7- 
dimethylpterin, 6-biopterin, D-(+)-neopterin, 6-hydroxym 
ethylpterin, pterin, isoxanthopterin, Xanthopterin, pterin-6- 
carboxylic acid, and oncopterin ((N'-(3-aminopropyl) 
biopterin). The structures of these pteridines are shown in the 
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As shown in Table 1, the above listed molecules all contain 
a pterin base with a variety of functional groups that can be 
bonded to the C6 carbon of the bi-cyclic pterin molecule 
forming the pteridine of interest. 
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In general, the method of the present invention involves the 
following steps: 
1) Preparing a urine sample for analysis; 
2) Separating the pteridines in the prepared sample by 
capillary electrophoresis (CE); and 
3) detecting pteridine levels in the sample with laser 
induced fluorescence (LIF). 
Sample preparation involves oxidation of the pteridines in 
the biological sample. The sample is additionally pH adjusted 
by alkalinizing the sample. The sample may be centrifuged 
and diluted prior to separation by capillary electrophoresis. 
The present invention is further directed to an apparatus 
that may be used to detect pteridine levels in a biological 
sample, e.g., a urine sample, by capillary electrophoresis 
laser induced fluorescence (CE-LIF). 
I. Sample Preparation 
According to some embodiments of the method of the 
present invention, a biological sample, e.g., a urine sample, 
which is known to contain pteridines is prepared for analysis 
via capillary electrophoresis-laser induced fluorescence (CE 
LIF). 
Pteridines in biological samples generally exist in three 
oxidative states. The most reduced biological state is the 
tetrahydropteridin form. According to the nomenclature in 
the art, a tetrahydropteridin form of biopterin, for example, is 
referred to as tetrahydrobiopterin and written as HB in short 
hand. An intermediate reduced biological state is the dihy 
dropteridin form. According to the nomenclature in the art, a 
dihydropteridin form of biopterin is referred to as dihydro 
biopterin and written as H-B in shorthand. Accordingly, 
reduced compounds are indicated by the prefixes dihydro 
tetrahydro-, etc., with numerals indicating the positions of 
the additional hydrogen atoms, if known. A tetrahydro-com 
pound is assumed to be substituted in the 5, 6, 7, and 8 
positions, and a dihydro-compound is assumed to be substi 




NH i S-C-C-CH, 
1s 8 OH OH HN N NH 
5,6,7,8-Tetrahydrobiopterin 
Biological samples may comprise pteridines in a fully oxi 
dized State. According to the nomenclature in the art, the fully 
oxidized form of biopterin is simply referred to as biopterin 
and written as B in shorthand. The structures of biopterin in its 
fully oxidized state, as the dihydrobiopterin intermediate 
reduced state, and the fully reduced tetrahydrobiopterin, are 
shown below: 




























HN N N 
H H 
Tetrahydrobiopterin (HB) 
In accordance with this invention, pteridines in the biologi 
cal sample, e.g., urine sample, are oxidized to their fully 
oxidized state. It has been discovered that fully oxidized 
pteridines produce a simpler sample matrix with less back 
ground interference, and are easily prepared and quantified. 
The oxidation treatment is sufficient to quantitatively oxidize 
pteridines that may be in their lower (e.g., dihydro or tetrahy 
dro) redox state in the sample to their fully oxidized state. In 
one aspect, the oxidation treatment is sufficient to oxidize 
tetrahydro and dihydropteridines into the fully oxidized state 
Such that the concentration of one or more pteridine com 
pounds being analyzed that exist in the sample in their fully 
oxidized state comprise at least about 90 wt % (or 95 wt %, or 
99 wt %, or 99.9 wt %) of the total of such pteridines in the 
sample. Stated another way, the total concentration of the 
pteridine compounds being analyzed that exist in the sample 
in the tetrahydro or dihydro (or other) reduced states is less 
than about 10 wt % of the total of such pteridine compounds 
in the sample. Preferably, oxidative treatment is sufficient to 
oxidize the pteridines being analyzed such that at least about 
95 wt % of the total of such pteridines in the sample are in the 
fully oxidized form (e.g., less than about 5 wt % of such 
pteridines are in the, e.g., tetrahydro or dihydro, reduced 
states), even more preferably at least about 99 wt % of the 
total of such pteridines in the sample are in the fully oxidized 
form, such as at least about 99.9 wt % of the total of such 
pteridines are in the fully oxidized form. It has been discov 
ered that the best results are achieved for early cancer screen 
ing if inaccordance with this invention all or essentially all of 
the pteridines are fully oxidized, by which it is meant 100 wt 
% or nearly 100% of the pteridine concentration, and it is 
meant of all the several known pteridine species. 
Accordingly, the invention involves treating the biological 
sample with an oxidizing agent in a concentration Sufficient 
such that at least about 90 wt % of the concentration of a 
pteridine compound in the biological sample is in its fully 
oxidized State, and that pteridine compound concentration is 
then detected. The pteridine compound which is oxidized to 
its fully oxidized state is selected from the group consisting of 
6,7-dimethylpterin, 6-biopterin, D-(+)-neopterin, 6-hy 
droxymethylpterin, pterin, isoxanthopterin, Xanthopterin, 
pterin-6-carboxylic acid, oncopterin ((N'-(3-aminopropyl) 
biopterin), and two or more of said compounds. In other 
words, in various embodiments one might focus on only one 
Such pteridine compound; and in other embodiments one 
might focus on several or all such pteridine compounds. For 
best results, all of these eight compounds are fully oxidized. 
Also, in this sense it is understood that each of these eight 
listed compounds may exist in the sample initially in a less 
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oxidized state having a different name. So, for example, when 
the process is described as oxidizing at least about 90 wt % of 
the biopterine concentration to its fully oxidized state, it is to 
be understood that it is described this way for clarity pur 
poses, and this encompasses and requires oxidizing at least 
about 90 wt % of the concentration of all the lower oxidized 
forms thereof (e.g., tetrahydropteridine and dihydropteri 
dine) to biopterine. The description therefore encompasses 
oxidizing at least about 90 wt % (95 wt %, or 99 wt %) of the 
lower oxidized forms of 6,7-dimethylpterin to the fully oxi 
dized state; oxidizing at least about 90 wt % (95 wt %, or 99 
wt %) of the lower oxidized forms of 6-biopterinto the fully 
oxidized state; oxidizing at least about 90 wt % (95 wt %, or 
99 wt %) of the lower oxidized forms of D-(+)-neopterin to 
the fully oxidized state; oxidizing at least about 90 wt % (95 
wt %, or 99 wt %) of the lower oxidized forms of pterinto the 
fully oxidized state; oxidizing at least about 90 wt % (95 wt 
%, or 99 wt %) of the lower oxidized forms of isoxanthopterin 
to the fully oxidized state; oxidizing at least about 90 wt % (95 
wt %, or 99 wt %) of the lower oxidized forms of xanthopterin 
to the fully oxidized state; oxidizing at least about 90 wt % (95 
wt %, or 99 wt %) of the lower oxidized forms of pterin-6- 
carboxylic acid to the fully oxidized state; oxidizing at least 
about 90 wt % (95 wt %, or 99 wt %) of the lower oxidized forms of oncopterin ((N'-(3-aminopropyl) biopterin) to the 
fully oxidized state. 
The pteridines in the biological sample, e.g., urine sample, 
may be oxidized by a variety of oxidation reagents, for 
example, iodine, peroxide, persulfate, nitrates, chlorites, per 
manganate, or iron(III) chloride. Oxidation of the pteridines 
to their fully oxidized state is preferably carried out by expos 
ing the biological sample containing pteridines to iodine. In 
Some embodiments, the oxidation solution contains elemen 
tal iodine and an iodine salt. Oxidation methods are disclosed 
in Trehan (J. Clin. Biochem. and Nut., 14, 195-203, 1993), 
Sawada (Clin. Chim. Acta, 138, 275-282, 1984), and Gold 
berg (J. Vet. Med. A., 34,481-486, 1987 and Pteridines, vol 1, 
29-35, 1989). 
In preferred embodiments, the oxidizing Solution com 
prises 4.0% (w/v) potassium iodide and 2.0% (w/v) iodine. 
The oxidizing solution may be prepared in bulk and stored in 
a dark container and sealed within a secondary container 
(such as aluminum foil) to avoid photo degradation of iodine. 
In preferred embodiments, the pteridines are oxidized by 
contacting the biological sample containing pteridines with a 
composition comprising 4.0% (w/v) potassium iodide and 
2.0% (w/v) iodine in a concentration that is sufficient to 
quantitatively oxidize the pteridines that exist in the sample in 
a reduced form. In preferred embodiments, the iodine con 
centration is present in a stoichiometric excess over the esti 
mated concentration of pteridine that is in a reduced form. 
Preferably, the molar ratio of iodine to the estimated concen 
tration of pteridine in the sample that is in a reduced form is at 
least about 1:1, such as at least about 2:1, preferably at least 
about 4:1. 
In some embodiments, oxidation of the pteridines in the 
biological sample occurs under alkaline conditions. The pH 
of the biological sample is adjusted to an alkaline condition 
because pteridines are only sparingly soluble or insoluble in 
acidic pH. The pH of the biological sample may be adjusted 
to an alkaline pH between about 7.5 and about 11, preferably 
between about 8 and about 10, even more preferably between 
about 9 and 9.8. Standard alkaline adjustment agents may be 
used. Such as Sodium hydroxide, potassium hydroxide, and 
amines such as tetramethylammonium hydroxide. 
In general, oxidation occurs to an extent Sufficient to quan 













oxidized state after about 30 minutes exposure to the oxidiz 
ing agent. Due to the potential photo activity of pteridines and 
urine, oxidation preferably occurs in dark environments. 
After oxidation and alkalinization, the sample is centri 
fuged. A biological sample that is subjected to alkalinization 
and oxidation generally contains insoluble material. The 
sample is centrifuged for a duration and centrifugal force 
Sufficient to separate the insoluble materials into a solid plug 
on the bottom of the vessel. The liquid is separated from the 
solid. The supernatant liquid is then diluted with sample 
buffer generally at a ratio of at least 1 part sample to 1 part 
sample buffer, but the dilution may be greater if the pteridine 
concentration is too high for the detector. 
II. Capillary Electrophoresis 
Capillary electrophoresis (CE) generally involves the 
application of high Voltages across buffer-filled capillaries to 
achieve separations by their charge and frictional forces and 
hydrodynamic radius. Operation of a high-performance cap 
illary electrophoresis (HPCE) system involves application of 
a high Voltage across a narrow bore capillary. The separation 
of compounds by capillary electrophoresis is dependent on 
the differential migration of analytes in an applied electric 
field. Voltages forestablishing the electric field generally vary 
from between about 10 kV and about 30 kV. 
The capillaries used are normally fused silica capillaries 
covered with an opaque external polymer protective coating 
to give them increased mechanical strength. A Small portion 
of this coating is removed to form a window for detection 
purposes. Removal of the polymer protective coating renders 
the capillary detection window transparent to visible light 
wavelengths and light wavelengths of the excitation source. 
The window is aligned in the optical center of the detector. 
Capillaries are typically between about 25 cm and about 200 
cm long, preferably between 25 cm and 100 cm long. Prefer 
ably, the window is between about 15 cm and about 100 cm 
from the sample introduction point, thereby defining an effec 
tive length of the capillary of sufficient length to separate the 
compounds of interest. Capillary inner diameters may vary 
from about 25 micrometers to about 300 micrometers. In 
embodiments of the present invention, the capillary inner 
diameter is preferably between about 25 micrometers and 
about 200 micrometers. Successful separations have occurred 
in capillaries having internal diameters of 50 micrometers 
and 75 micrometers. On standard commercial high-perfor 
mance capillary electrophoresis (HPCE) instruments, the 
capillary is typically held in a housing device as a cartridge to 
facilitate ease of capillary insertion into the instruction and to 
protect the delicate detection window area. 
The capillary is filled with a buffer solution which conducts 
current through the inside of the capillary. The ends of the 
capillary are dipped into reservoirs filled with the buffer. 
Electrodes made of an inert material Such as platinum are also 
inserted into the buffer reservoirs to complete the electrical 
circuit. Preferred operating buffers include tris(hydroxym 
ethyl)aminomethane (“Tris'), 2-N-(morpholine)ethane 
Sulfonic acid, N-(2-acetamido)iminodiacetic acid, pipera 
Zine-N,N'-bis(2-ethanesulfonic acid, N(2-acetamido)-2- 
aminoethanesulfonic acid, (2-aminoethyl)trimethyl 
ammonium chloride hydrochloride, N.N-bis(2-hydroxy 
ethyl)-2-aminoethane sulfonic acid, N2-hydroxy 
ethylpiperzine-N'-2-ethanesulfonic acid, N-tris 
(hydroxylmethyl)methylglycine, N N-bis(2- 
hydroxyethyl)-glycine, 2-(N-cyclohexylamino) 
ethanesulfonic acid, and mixtures thereof. 
In some embodiments, the running buffer is a Tris buffer in 
a concentration between about 0.05 Mandabout 0.2M, pref 
erably about 0.1 M. The running buffer may additionally 
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comprise borate, phosphate, or acetate in a concentration 
sufficient to carry a current, such as between about 0.01 Mand 
about 0.15 M.Tris-borate is a commonly used running buffer. 
The running buffer may additionally comprise a complex 
ing agent, such as ethylenediamine tetraacetic acid. It has 
further been found that the concentration of EDTA in the 
buffer influences the separation of pteridines while in a free 
condition. Specifically, concentrations of up to about 2 mM 
EDTA enhances the separation of the two isomers, isoxan 
thopterin and Xanthopterin. 
The pH of the running buffer is generally between about 
7.0 and about 12.0, preferably between about 8.0 and about 
10.0, such as between about 9.0 and about 10.0. The running 
buffer is generally from 8.0 to 10 to assist in the systematic 
isolation of specific pteridines within the compounds of inter 
est. Standard alkaline adjustment agents may be used, such as 
Sodium hydroxide, potassium hydroxide, and amines Such as 
tetramethylammonium hydroxide. The optimized condition 
for separating urinary pteridines uses a running buffer with 
pH of 9.63+0.02. 
Temperature has also been found to influence the separa 
tion of pteridines due to the change of mobility of the pte 
ridines at various temperatures. The temperature of the pte 
ridines during separation therefore should be in the range of 
from about 18°C. to 30°C., with from about 22°C. to 25°C. 
being preferred. The temperature may be regulated using a 
cooling system to counteract Joule heating caused by the 
resistance of the Voltage through the electrolyte system. 
Cooler systems that effectively counteract Joule heating are 
preferred since the analyte peaks are sharper and more 
resolved. 
The electrophoretic separation of pteridines in the biologi 
cal sample begins with sample injection. The sample is pre 
pared, e.g., oxidized and alkalinized, as described above and 
injected into the capillary via gravimetric injection, electro 
kinetic injection, pressure, or Suction. Even though electro 
kinetic injections can provide an on-line concentration of 
analytes at low concentrations, it is a very selective injection 
technique and the amount of analyte injected is dependent on 
the electro mobility of the analyte, which makes the injection 
biased toward analytes having high electromobilities, thereby 
overweighting the concentrations thereof in the analyzed 
sample. Relatively, gravimetric injection is a less biased tech 
nique, where a true composition of the sample may be 
observed at the expense of a more diluted injection. To 
accomplish gravimetric injection, the sample is raised higher 
than the waste reservoir. The sample injection end of the 
capillary is placed into the sample vial and through capillary 
and siphoning action, the sample is introduced. Experimental 
results indicate that injection for 10 sec at a height of 17.5 cm 
introduced roughly 5-7 nL of sample. 
In preferred embodiments, separation of pteridines from 
the sample occurs at electrophoretic potential (EP) in a range 
between about 20 kV and about 30 kV, such as between 24 
and 26 kV. In a capillary having an effective distance between 
the sample injection point and the detection window between 
about 20 cm and about 40 cm, effective separation of pte 
ridines in a biological sample can be achieved in 10 to 20 
minutes. Empirical results to date indicate that separation 
efficiency of greater than 100,000 theoretical plates may be 
achieved using the capillary electrophoretic separation 
method of the present invention. 
III. Laser Induced Fluorescence 
In the method of the present invention, the electrophoreti 
cally separated pteridines are detected via lased induced fluo 
rescence. The fluorescence produced by the sample is isolated 













comprising distinct peaks representing the migration time of 
each pteridine in the sample. FIG. 1 is a schematic design 
detailing the optical setup of the apparatus according to one 
embodiment of the invention. 
In general, LIF comprises irradiating the pteridine contain 
ing running buffer with radiation within the wavelength range 
between 270 nm and 450 nm, such as between about 270 nm. 
and about 350 nm or between about 300 nm and about 450 
nm, to induce fluorescence of the pteridines when a plug of a 
particular pteridine passes through the detection window. In 
Some embodiments, the excitation source for Laser Induced 
Fluorescence (LIF) is a helium-cadmium laser operating in 
the range of about 320 to 330 nm, with about 325 nm being 
most preferred. One such laser is the Melles Griot 
Omnichrome Series-74, 325 nm laser (HeCd laser, 35 mW 
power, Carlsbad, Calif., USA). In some embodiments, the 
excitation source is a Solid state laser in the wavelength range 
of about 300 nm to 450 nm, preferably about 350 nm. One 
such laser is an Inca brand laser available from Xiton Photo 
nics GmbH of Kaiserlautern, Germany. In preferred embodi 
ments, the excitation source has a power output of at least 
about 1 mW, at least about 10 mW, such as between about 1 
mW and about 40 mW, between about 10 mW and about 40 
mW, preferably between about 20 mW and about 25 mW. The 
excitation source may emit polarized or non-polarized light. 
In preferred embodiments, the excitation source emits non 
polarized light. Non-polarized laser light is preferred since 
non-polarized light scatters less light upon impinging the 
capillary wall. 
The CE-LIF apparatus comprises a filtration device 
capable of transmitting laser light of a desired wavelength. In 
general, the filtration device comprises aband pass filter that 
isolates and transmits the desired wavelength and attenuates 
all other wavelengths. In some preferred embodiments, the 
desired laser wavelength is 325 nm. A band pass filter suitable 
for the apparatus of the present invention is a 325 nm band 
pass filter (Ealing, Holliston, Mass.; model UG-11). Several 
other types of band pass filters are available from Thorlaps of 
Newton, N.J., for example part number FL355-10 (laser line 
filter, CWL=355=/12 nam, FWHM-10–/-2 nmi; family: 0.1" 
UV laser line filters). Ultraviolet scan data reveal that some 
pteridines absorb from about 200 to about 360 nm, with a 
Aaround 350-360 for most. The excitation wavelengths of 
interest in the present method are therefore in the range of 
about 300 to about 450 nm. 
The CE-LIF apparatus comprises an optical system for 
focusing the filtered, non-polarized laser onto the detection 
window of the capillary, the pathway by which the intended 
sample is separated and exposed to the filtered, non-polarized 
laser via a detection window on the capillary. The optical 
system comprises a focal length. Preferably, the focal length 
is as short as possible to reduce the amount of scatter or stray 
layer. In preferred embodiments, the optical system com 
prises, for example, a 2.0 cm focal length lens. 
The high powered laser may have substantial scatter light. 
In view thereof, the CE-LIF apparatus preferably comprises 
an optical iris diaphragm positioned between the focal lens 
and the detection window of the capillary. The optical iris is 
positioned to cut off scatter light from the laser. A currently 
preferred iris is a 25 mm (outer diameter) High Performance 
Zero Aperture Series Iris Diaphragm available from Edmund 
Optics of Barrington, N.J. The iris is not narrowly critical to 
carrying out the invention; it reduces background noise to 
make the analysis more sensitive. It should be large enough to 
block all of the potential background and scattered light and 
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close sufficiently to make the effective field of view small 
enough to allow only the width of the laser or emitting fluo 
rescence through. 
The CE-LIF apparatus comprises a sample holder with a 
detection window that facilitates the mounting of an electro- 5 
phoresis capillary. 
The CE-LIF apparatus comprises a capillary electrophore 
sis device as described above that is capable of separating the 
specific compounds of interest (pteridines) within the bio 
logical sample and delivering the sample to the detection 
window of the capillary mounted within the sample holder. 
The CE-LIF apparatus preferably comprises a confocal 
lens having greater than 10x magnification placed in the 
range of 45 to 90 degrees (90 degrees being preferred) from 
the laser path to collect and focus fluorescence emission from 
the sample. In preferred embodiments, the confocal lens has 
greater than 20x magnification, greater than 30x magnifica 
tion, or even greater than 40x magnification, such as 43x 
magnification. An exemplary confocal lens is available from 
Bausch and Lomb, 0.6 NA, 40x. 
The CE-LIF apparatus preferably comprises a second fil 
tration means for filtering fluorescence generated by impuri 
ties and other sources of fluorescence. The second filtration 
device is used to transmit fluorescence from pteridines while 
blocking fluorescence from non-pteridine sources. The sec 
ond filtration means may be a bandpass filter designed to 
transmit pteridine fluorescence. The wavelengths transmitted 
are generally between 400 and 539 mm. Such abandpass filter 
is available from Ealing, model 35-532. 
The CE-LIF apparatus preferably comprises a physical 
optical iris diaphragm located between the bandpass filter/ 
confocal lens and the fluorescent light collection device. The 
iris diaphragm removes any scattering either from the filtered 
non-polarized laser or from any fluorescence generated by the 
device. This iris is typically the same as the optical iris dia 
phragm positioned between the focal lens and the detection 
window of the capillary. 
The CE-LIF apparatus comprises a detection means for 
detecting the filtered fluorescence emission generated by the 
pteridines in the samples of interest. A preferred light detec 
tion means is a photomultiplier tube, which is an extremely 
sensitive detector of light in the ultraviolet, visible, and near 
infrared ranges of the electromagnetic spectrum. A commer 
cially available PMT is a Hammatsu PMT. Type R928, No. 
IG6957. 
The current signal from the fluorescent light detection 
device is preferably converted to a voltage via a current to 
Voltage (I to V) converter, which communicates the raw out 
put of electrons produced in the fluorescent light detection 
device produced by fluorescence from the compounds of 
interest undergoing fluorescent decay to the digital input of 
the device collecting the output. 
The CE-LIF apparatus preferably comprises a control 
means for independently controlling the stations of the laser 
focal lens, capillary mount, collection lens and detector to 
prevent any mechanical cross-talk from one stage to the oth 
ers that may adversely affect the resulting data. 
The combination of a physical optical iris diaphragm 
placed between the focal lens and the capillary detection 
window, a high magnification confocal lens, and a physical 
optical iris diaphragm placed between the confocal lens and 
the light collection device provides an extremely stable base 
line, which in turn yields high signal to noise ratios (S/N) and 
low limits of detection. According to some empirical results, 
the baseline is less than 1 mV, which enables low limits of 
detection. The limits of detection reported in the below 













While the invention has been described in connection with 
specific embodiments thereof, it will be understood that the 
inventive methodology is capable of further modifications. 
This patent application is intended to cover any variations, 
uses, or adaptations of the invention following, in general, the 
principles of the invention and including such departures 
from the present disclosure as come within known or custom 
ary practice within the art to which the invention pertains and 
as may be applied to the essential features herein before set 
forth and as follows in Scope of the appended claims. 
Having described the invention in detail, it will be apparent 
that modifications and variations are possible without depart 
ing from the scope of the invention defined in the appended 
claims. 
EXAMPLES 
The following non-limiting examples are provided to fur 
ther illustrate the present invention. 
Example 1 
The following example describes a high performance cap 
illary electrophoresis (HPCE) separation of pteridines in a 
biological sample with laser-induced fluorescence (LIF) 
detection method (HPCE-LIF) for quantitative analysis of 
pteridines in urine samples. HPCE-LIF was used to investi 
gate pteridine level patterns in 38 urine samples from a variety 
of cancer patients. Some types of cancer were not studied 
mainly due to the unavailability of urine samples and not the 
limitation of the technique. In order to assure that the pteri 
dine levels represent the physiological concentration, the 
amount of pteridines was reported here as a ratio of pteridine 
to creatinine See Shi H. Ma Y., Ma Y. A Simple and Fast 
Method to Determine and Quantify Urinary Creatinine, Anal. 
Chim. Acta., 1995, 312, pp. 79-83. 
Materials and Methods. 
Chemicals. 
Pteridine standard solutions of 6-biopterin, D-(+)-neop 
terin, pterin, isoxanthopterin, Xanthopterin pteridine were 
purchased from Sigma-Aldrich (St. Louis, Mo.). Standard 
solutions of 6,7-dimethylpterin and 6-hydroxymethylpterin 
were purchased from Schircks Laboratories (Jona, Switzer 
land). Boric acid and Tris(hydroxymethyl)aminomethane 
were purchased from Sigma-Aldrich (St. Louis, Mo.). EDTA 
disodium salt, iodide, potassium iodine, sodium hydroxide 
and sodium phosphate dibasic were purchased from Fisher 
(Fair Lawn, N.J.). Ultrapure water was obtained using a 
Milli-Q Advantage(R) A10 and Millipore Elix(R) water purifi 
cation system. 
pH Measurement. 
All pH measurements were performed on an Accumets(R) 
Excel XL-15 pH meter that was standardized using pH stan 
dards 4, 7, and 10 (Fisher ScientificTM). Standard creatinine 
for creatinine analysis was purchased from Sigma-Aldrich.R. 
(Milwaukee, Wis.). 
Buffer Preparation. 
A 0.1 M Tris/0.1 Mborate/2 mM EDTA running buffer was 
prepared and pH was adjusted to 9.63+0.02 using 2.0 M 
NaOH. A 50 mM aqueous solution of NaHPO, sample 
buffer was prepared and pH was adjusted to 7.70+0.02 using 
concentrated phosphoric acid. This was used to dilute both 
standards and samples. A 15 mM. KHPO solution was pre 
pared and pH was adjusted to 6.4 using 1.0 M NaOH. This 
was used as the running buffer for creatinine analysis. The 
creatinine sample dilution buffer was prepared in exactly the 
same way as the running buffer except that 2% EDTA was 
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present in sample dilution buffer. EDTA was used to complex 
the metalions in the urine sample so that these ions would not 
form complexes with creatinine. All the buffers were filtered 
with a 0.45 um membrane and degassed before use. 
Standard Preparation. 
To prepare pteridine standard Solutions, 2 mg of pteridine 
standard was dissolved in a solution consisting of 0.3 mL of 
1.0 M sodium hydroxide and 9.7 mL of sample buffer. A 
standard mixture was then prepared by combining equal 
molar concentrations of each standard and diluted to a final 
concentration of 5.0x10M with the sample buffer. A dilu 
tion series of this stock solution was used to generate calibra 
tion curves. Standard creatinine stock Solution was prepared 
by dissolving 50 mg creatinine into 50 mL sample dilution 
buffer to make the creatinine concentration 100 mg/dL. This 
standard stock solution was diluted to an appropriate concen 
tration with the sample dilution buffer. 
Oxidizing Solution Preparation. 
The oxidizing solution consisted of 4.0% potassium iodide 
and 2.0% iodine (w/v). It was prepared by dissolving 0.6008 
g of KI in 15 mL of Milli-Q water. Once the KI was dissolved, 
0.3025g of I was added to the solution. The solution was then 
stirred (for about 1 h) until the I was completely dissolved. 
The final Solution was stored in an amberglass vial, and the 
cap was wrapped with ParafilmR). The vial was wrapped with 
aluminum foil to avoid photo degradation of the iodine. 
Urine Sample Preparation. 
Urine samples from cancer patients who did not undergo 
chemical or radiation therapy were obtained from Ellis Fis 
chel Cancer Center, Columbia, Mo. The normal urine 
samples were collected from student volunteers at Missouri 
S&T who did not take any medications including vitamin 
Supplements. The demographic distribution of cancer 
patients and normal Subjects were mainly from nearby cities. 
The age distribution of cancer patients was from 26-70 y, and 
the range for normal Subjects was 22-45 y. There was no 
dietary or exercise restriction performed among the control 
group or the cancer patients. The urine from the cancer 
patients represented breast (12), lung (9), colon (4), rectal (2), 
pancreatic (1), ovarian (3), non-Hodgkins lymphoma (4), 
esophageal (4), bladder (1), and kidney (1) cancers. All the 
samples were stored in a freezer at -80° C. Prior to analysis, 
the samples were removed from the freezer and brought to 
room temperature. A 1000 uL aliquot of urine sample was 
taken using a micropipette and placed in a 1.5 mL yellow 
microcentrifuge tube. Then 400 uL of the oxidizing solution 
and 100 uL of 2.0 M NaOH were added to the sample and 
mixed well. The sample mixture was incubated at 4°C. for 30 
min and centrifuged at 5000 rpm for 20 minat 4°C. Then 500 
LL of the Supernatant was placed in a new vial, and 500LL of 
sample buffer was added to it. It was mixed thoroughly and 
injected directly into the CE for analysis. Further dilutions 
were made in some samples. 
Capillary Electrophoresis Laser Induced Fluorescence 
System (CE-LIF). 
A home-built capillary electrophoresis LIF system was 
used for this study. A depiction of the device is provided in 
FIG.1. A Melles Griot Omnichrome Series-74, 325 nm laser 
(HeCd laser, 35 mW power, Carlsbad, Calif., USA) was used 
for excitation. The stray and scattered light from the nonpo 
larized laser were removed using a 325 nm band-pass filter 
(Ealing, Holliston, Mass.; model UG-11). The laser was 
focused on the capillary window with a 2.0 cm focal length 
lens. Prior to impinging the detection window of the capillary, 
the laser beam passed through an iris, which remove Scatter 
light from the laser. The first iris is positioned to provide the 













is the diameter of the opening. It is reduced to permit only the 
laser beam through. The second iris is positioned to provide 
the only pathway that fluorescence can get to the detector 
(PMT). Again, the adjustment is the diameter of the opening 
to reduce the effective field of view to only include light 
passing through the inner diameter of the capillary, which 
contains the sample and emits the fluorescence. 
The fluorescence emission was collected by a microscopic 
objective and focused onto a R982 Hamamatsu photomulti 
plier tube (Bridgewater). The microscopic objection com 
prises a confocal lens having 40 or 43X magnification, which 
choice depended upon the experimental conditions. Back 
ground noise was minimized using a band-pass filter (400 
539 nm, Ealing, model 35-532). A second iris is placed after 
the band pass filter and confocal lens (43X magnification) in 
order to reduce scatter light from the capillary. The resulting 
output current from the photomultiplier tube was converted to 
a Voltage signal through a home-built current-to-voltage con 
Verter. The analog signal was then digitalized though a Log 
ger Pro analog-to-digital converter (Verniers Software and 
Technology, Beaverton, Oreg.). The data were collected 
using Logger Pro 3.1 data collection Software. 
Creatinine Analysis. 
Creatinine analysis was performed following a method that 
was previously developed in our group. See Shi H. MaY., Ma 
Y., A Simple and Fast Method to Determine and Quantify 
Urinary Creatinine, Anal. Chim. Acta., 1995, 312, pp. 79-83. 
A Beckman P/ACE capillary electrophoresis instrument 
equipped with ultraviolet absorbance was used for creatinine 
analysis. The detection wavelength was set at 214 nm. The 
capillary column (Polymicro Technologies, Phoenix, Ariz.) 
used was 60 cmx50 um inner diameter fused silica tubing 
with an effective length of 35 cm. Electrophoresis was carried 
out at 20 kV. Urine samples were diluted with sample dilution 
buffer and directly injected into the HPCE column. The data 
were collected and processed by 32 Karat Software ver, 5.0 
(Beckman, Inc.). Peaks were identified by both retention time 
and standard addition. 
Pteridine Analysis Using CE-LIF. 
A70 cm lengthx50um inner diameter fused silica capillary 
(Polymicro Techniques, Phoenix, Ariz., USA) was used for 
separation. First, the new capillary was rinsed with 1.0 M 
NaOH for 15 min, followed by Milli-Q water for 5 min. Next, 
it was rinsed with 1M HCl for 15 min, with Milli-Q water for 
5 min, and finally with running buffer for 15 min. A 1 cm 
section of the polymer coating was burned off at 35 cm from 
the cathode end, forming the detection window and leaving an 
effective capillary length of 35 cm. Samples were injected 
into the capillary by the gravimetric method. Samples were 
injected 17.5cm from the top of the sample to the instrument 
table with an injection time of 10 s. Electrophoresis was 
carried out at 26 kV (371 V/cm) for 20 min. After each 
injection, the capillary was regenerated by flushing with 0.2 
M NaOH for 1 min, followed by a 2 min water rinse, and 
finally by a 2 min running buffer rinse. The individual pteri 
dine peaks in the urine samples were identified by retention 
time comparisons and standard addition and obtained from 
the Logger Prosoftware. 
Statistical Analysis. 
Pteridine concentrations were determined by linear regres 
sion against experimentally generated calibration curves. The 
basic statistical information Such as mean, variance, and 
pooled variance of each pteridine for both cancer and normal 
urine samples were calculated by Minitab Software. Statisti 
cal hypothesis testing was conducted to analyze the data. The 
null hypothesis was that the mean pteridine levels in cancer 
samples are lower than or equal to those in normal urine. The 
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alternative hypothesis was that mean pteridine levels in can 
cer samples are higher than those in normal samples. The P 
values (last raw in Table 2) were calculated for all samples. 
The null hypothesis was rejected, and the results demonstrate 
that the alternative is significant at a 5% significance level if 5 
the P values0.05. 
TABLE 2 
Basic Statistical Summaries of Each 10 
Pteridine for Cancer and Normal Urine Samples 
Pteridine 
6,7- 6 
dimethyl hydroxymethyl D-(+)- 15 pterin 6-biopterin pterin neopterin 
Mean Cancer 7.41E-04 8.96E-04 4.81E-04 1.14E-O3 
(n = 38) 
Mean Normal 2.79E-05 1.14E-04 4.83E-OS 2.37E-04 
(n = 17) 
Variance 8.81E-O6 2.67E-06 9.2OE-07 1.16E-05 20 
Cancer 
Variance 3.3OE-09 114E-08 1.57E-09 1.2OE-07 
Normal 
Pooled 6.15E-06 1.87 E-06 6.43E-07 8.16E-06 
Variance 
t Stat O.986 1958 1849 1079 25 




Isoxantho Xantho carboxylic 
Pterin pterin pterin acid 
Mean Cancer 6.OOE-04 3.37E-O2 S.S9E-03 2.54E-04 
(n = 38) 
Mean Normal 175E-04 106E-O3 1.13E-O3 1.25E-04 35 
(n = 17) 
Variance S.28E-07 1.1OE-03 3.94E-OS 9.109E-08 
Cancer 
Variance 2.93E-08 S.66E-07 1.47E-O6 198E-08 
Normal 
Pooled 3.78E-07 7.68E-04 2.79E-0S 6.957E-08 
Variance 40 
t Stat 2.373 4.040 2.891 1682 
P (T<= t) O.O11 8.67E-OS O.OO3 O.049 
one tail 
The standard mixture of 8 pteridines was first injected into 45 
the CE, and the elution order was obtained. The detection 
limit, linear equations and R values are given in Table 3. 
TABLE 3 
50 
Calibration Data for Each Pteridine 
Limit of Linear Equations of 
Pteridine Detection Calibration Curves R2 
6,7-dimethyl 2.5 x 100 y = 1.2383 x 10°X + 0.9642 0.98.28 ss 
pterin 
6-biopterin 2.5 x 109 y = 9.2704 x 10X + 0.3174 O.9911 
6-hydroxy- 2.5 x 100 y = 7.6386 x 10X + 0.3339 O.9923 
methyl pterin 
D-(+)-neopterin 2.5 x 109 y = 9.2866 x 10X + 0.2902 O.9947 
Pterin 2.5 x 109 y = 7.9057 x 10X + 0.3014 O.9936 
Isoxanthopterin 2.5 x 109 y = 3.6299 x 10X + 0.0897 0.9987 60 
Xanthopterin 2.5 x 100 y = 6.5796 x 10X + 0.0863 O.9988 
Pterin-6- 4.72 x 109 y = 1.6335 x 10X + 0.3788 O.9988 
carboxylic acid 
The electopherogram is shown in FIG. 2. The number of 65 
theoretical plates for the separation was determined to be 
130,000. FIG. 2 showed that the 6,7-dimethylpterin eluted 
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first and the pterin-6-carboxylic acid eluted last. FIGS. 3-12 
show the box plots of various pteridines in samples from both 
cancer patients and healthy Subjects. Creatinine calibration 
graph had a linear range from 0 to 20 mg/dL and R was 
0.9819. Creatinine levels in cancer patients and healthy sub 
jects were shown in FIG. 13. 
Table 2 provided basic statistical information such as 
mean, variance, and pooled variance of each pteridine for 
both cancer and normal urine samples. The key objective of 
this work was to determine whether there is any significant 
difference between levels of pteridine in cancer urine samples 
and those in normal urine samples. FIG. 3 showed the box 
plot of 6,7-dimethylpterin. In the urine samples of cancer 
patients, 3 outliers are disregarded, there was no significant 
difference in levels of 6,7-dimethylpterin in cancer and nor 
mal samples. The P value of 6-biopterin was 0.028. So the 
mean value of 6-biopterin in the cancer samples was signifi 
cantly greater than that in the normal samples (FIG. 4). FIG. 
5 indicated that, even after the outliers were removed, the 
6-hydroxymethylpterin level in cancer patients was higher 
than the normal (P=0.035). FIG. 6 showed that the D-(+)- 
neopterin level was higher in cancer patients than in normal 
subjects but P value was 0.143. Therefore, the D-(+)-neop 
terin level in cancer urine samples was not significantly 
greater than normal because D-(+)-neopterin variance was 
higher in cancer. The pterin levels in cancer were significantly 
higher than normal (P=0.011) (FIG. 7). 
In both cancer and normal urine samples, levels of Xantho 
pterin and isoxanthopterin levels were higher than those of 
other pteridines, as indicated by the y axes of the box plots. 
The box plot for Xanthopterin and isoxanthopterine (FIGS. 8 
and 9) showed that levels in the cancer urine samples were 
much higher than in the normal urine samples (P-8.7x10. 
and 2.8x10, respectively). Hanet al. previously showed that 
lower isoxanthopterin levels in cancer patients compared to 
the normal. See Han F., Huynh B. H., Shi H., Lin B., MaY., 
Pteridine Analysis in Urine by Capillary Electrophoresis 
Using Laser-Induced Fluorescence Detection, Anal. Chem. 
1999, 71, pp. 1265-9. But they analyzed only 9 cancer patient 
urine samples and this may be due to outliers present in the 
data. The pterin-6-carboxylic acid was not significant 
(P=0.049) (FIG. 10). 
A comparison of the P values of each pteridine demon 
strates that Xanthopterin and isoxanthopterin were much 
lower than those of the other pteridines. Thus, their levels in 
breast cancer (n=12) and lung cancer (n=9) urine samples 
were checked (FIGS. 11 and 12). Table 4 showed the P values 
calculated for various combinations. Xanthopterin and isox 
anthopterin levels cannot be used to differentiate lung cancer 
from breast cancer. These biomarkers were significantly high 
in breast and lung vs. normal (P<0.05). 
TABLE 4 
Xanthopterin and isoxanthopterin P values for various 
combinations of lung cancer, breast cancer, and 
normal urine samples 
Pteridine Combination P 
Xanthopterin Lung Cancer v. Breast Cancer O.1311 
Lung Cancer v. Normal 8.S1E-OS 
Breast Cancer v. Normal 4.18E-OS 
Isoxanthopterin Lung Cancer v. Breast Cancer O.04898 
Lung Cancer v. Normal O.OOO287 
Breast Cancer v. Normal O.OO7288 
This work analyzed 8 pteridines in urine samples from 
cancer patients and healthy Subjects. Some pteridine levels in 
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the urine samples of the cancer patients were higher than 
those of healthy subjects. More specifically, 6-biopterin, 
6-hydroxymethylpterin, pterin, Xanthopterin and isoxantho 
pterin levels in cancer samples were significantly higher than 
normal. Also, levels of Xanthopterin and isoxanthopterin in 
both cancer patients and healthy Subjects were higher than 
other pteridines. The foregoing demonstrates that the inven 
tion is effective for using pteridines as biomarkers for early 
cancer Screening. 
Example 2 
The foregoing method was also performed to analyze for 
cancer by detection of oncopterin. Cancer and cancer-free 
urine samples were analyzed and plotted as shown in FIG. 14. 
The experimental conditions were as follows: Running 
buffer: 0.1 M Tris-0.1 Mborate-2 mM EDTA, pH 9.63; Cap 
illary: 50 mm i.d.x70 cm (35 cm effective column length): 
Injection: gravimetric (17.5 cm from the of the sample to the 
instrument table and the injection time was 10 seconds). 
Running voltage: 371 V/cm; LIF detection at 325 nm/445 nm. 
(ex/em); concentration of each pteridine standard: 10x10 
M. FIG. 14 shows these eight known peaks in the cancer 
samples and has them labeled 1-8: 1) 6,7-dimethylpterin; 2) 
6-biopterin; 3) D-(+)-neopterin; 4) 6-hydroxymethylpterin; 
5) Pterin; (6) isoxanthopterin; 7) xanthopterin; (8) carboxyp 
terin. FIG. 14 also shows two peaks not identified with any of 
(1) through (8). 
Previous work shows that oncopterin is elevated in patients 
with cancer. Since this experiment ran cancer and control 
samples side-by-side, one would expect to see a distinct dif 
ferent between the electropherograms. The peak between the 
peaks labeled 1 (6.7 DMP) and 2 (biopterin) is expected to 
identify oncopterin in view of the structural similarity 
between oncopterin and biopterin. It is expected this will be 
confirmed by analysis of an oncopterin standard. Consistent 
with this identification is that propylamine which differenti 
ates oncopterin from biopterin could shift its elution time in 
an unpredictable manner, which would manifest itself in the 
second peak marked with an arrow in FIG. 14. 
When introducing elements of the present invention or the 
preferred embodiments(s) thereof, the articles “a”, “an', 
“the' and “said are intended to mean that there are one or 
more of the elements. The terms “comprising”, “including 
and “having are intended to be inclusive and mean that there 
may be additional elements other than the listed elements. 
In view of the above, it will be seen that the several objects 
of the invention are achieved and other advantageous results 
attained. 
AS Various changes could be made in the above composi 
tions and processes without departing from the scope of the 
invention, it is intended that all matter contained in the above 
description and shown in the accompanying drawings shall be 
interpreted as illustrative and not in a limiting sense. 
What is claimed is: 
1. A method for Screening for cancer in a mammal, the 
method comprising: 
obtaining a biological sample from the mammal; 
treating the biological sample with an oxidizing agent in a 
concentration sufficient such that at least about 90 wt % 
of concentration of oncopterin (N2-(3-aminopropyl) 
biopterin) in the biological sample is in its fully oxidized 
State; 
quantitatively measuring a concentration of oncopterin 
(N2-(3-aminopropyl) biopterin) in said biological 
sample by capillary electrophoresis-lased induced fluo 













phoresis using laser-induced fluorescence (CE-LIF) to 
cause the oxidized portion of said concentration of said 
oncopterin (N2-(3-aminopropyl) biopterin) to emit fluo 
rescent light, detecting the emitted fluorescence light, 
and analyzing the emitted fluorescence light to deter 
mine the concentration of the oncopterin (N2-(3-amino 
propyl) biopterin) in the biological sample; and 
comparing the concentration of oncopterin (N2-(3-amino 
propyl) biopterin) in the sample to an expected concen 
tration of oncopterin (N2-(3-aminopropyl) biopterin) 
for either a healthy or cancer-bearing mammal of the 
same species; 
wherein the CE-LIF comprises directing laser light 
through a filter, a focal lens, and an iris of a first optical 
system and into an electrophoresis capillary containing 
the biological sample to irradiate and cause fluorescence 
from the biological sample; and receiving fluorescence 
emission from the biological sample through a second 
optical system comprising a confocal lens having a mag 
nification greater than 20x and an iris which focus emit 
ted fluorescence onto a photomultiplier tube as a light 
collection device for collecting fluorescent light emitted 
from the pteridine in the biological sample. 
2. The method of claim 1 wherein the biological sample is 
a urine sample. 
3. The method of claim 1 wherein the subjecting the sample 
to CE-LIF comprises: 
injecting the biological sample containing the oxidized 
portion of pteridine into a capillary; 
electrophoretically separating the oxidized portion of pte 
ridine in the capillary by applying an electric field hav 
ing a minimum voltage of 10 kV; and 
irradiating the separated sample with non-polarized laser 
light from an excitation source having a power output of 
at least 1 mW. 
4. The method of claim 1 wherein the treating the biologi 
cal sample with the oxidizing agent is in a concentration 
sufficient such that at least about 95 wt % of said concentra 
tion of said pteridine compound in the biological sample is in 
its fully oxidized state. 
5. The method of claim 1 wherein the treating the biologi 
cal sample with the oxidizing agent is in a concentration 
sufficient such that at least about 99 wt % of said concentra 
tion of said pteridine compound in the biological sample is in 
its fully oxidized state. 
6. The method of claim 1 wherein the pteridine compound 
concentration is quantitatively oxidized by contacting the 
biological sample with elemental iodine. 
7. The method of claim 1 wherein the biological sample is 
combined with a sample matrix having a high ionic strength. 
8. The method of claim 7 wherein the sample matrix is 
phosphate buffer. 
9. The method of claim 1 further comprising detecting 
concentration levels of pteridine compounds other than onco 
pterinto determine what type of cancer that the mammal may 
develop. 
10. The method of claim 1 wherein the CE-LIF causes the 
oncopterin to be separated from other species in the biologi 
cal sample matrix. 
11. A method for Screening for cancer in a mammal, the 
method comprising: 
obtaining a biological sample from the mammal; 
treating the biological sample with an oxidizing agent in a 
concentration sufficient to fully oxidize oncopterin (N2 (3-aminopropyl) biopterin) in the biological sample: 
quantitatively measuring a concentration of oncopterin 
(N2-(3-aminopropyl) biopterin) in said biological 
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sample by capillary electrophoresis-lased induced fluo 
rescence by Subjecting the sample to capillary electro 
phoresis using laser-induced fluorescence (CE-LIF) to 
cause the oxidized portion of said concentration of said 
oncopterin (N2-(3-aminopropyl) biopterin) to emit fluo- 5 
rescent light, detecting the emitted fluorescence light, 
and analyzing the emitted fluorescence light to deter 
mine the concentration of the oncopterin (N2-(3-amino 
propyl) biopterin) in the biological sample; and 
comparing the concentration of oncopterin (N2-(3-amino- 10 
propyl) biopterin) in the sample to an expected concen 
tration of oncopterin (N2-(3-aminopropyl) biopterin) 
for either a healthy or cancer-bearing mammal of the 
same species; 
wherein the CE-LIF comprises directing laser light 15 
through a filter, a focal lens, and an iris of a first optical 
system and into an electrophoresis capillary containing 
the biological sample to irradiate and cause fluorescence 
from the biological sample; and receiving fluorescence 
emission from the biological sample through a second 20 
optical system comprising a confocal lens having a mag 
nification greater than 10x and an iris which focus emit 
ted fluorescence onto a photomultiplier tube as a light 
collection device for collecting fluorescent light emitted 
from the pteridine in the biological sample. 25 
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